Meronem powder solution 1g vials, 10pcs

Composition

Active ingredient:

meropenem trihydrate;

Auxiliary substances:

sodium carbonate (anhydrous) – 208 mg

Pharmacological action

Meronem has an antibacterial effect.

Indications

Meronem® is indicated for the treatment of the following infectious and inflammatory diseases caused by one or more meropenem-sensitive pathogens in children (older than 3 months) and adults:

• pneumonia, including nosocomial pneumonia;
• urinary tract infections;
• abdominal infections;
• infectious and inflammatory diseases of the pelvic organs, such as endometritis;
• infections of the skin and its structures;
• meningitis;
• septicemia.

Empirical treatment of adult patients with suspected infection with symptoms of febrile neutropenia in monotherapy or in combination with antiviral or antifungal drugs.

The effectiveness of Meronem® has been proven both in monotherapy and in combination with other antimicrobial agents in the treatment of polymicrobial infections.

Use during pregnancy and lactation

Pregnancy

The safety of using Meronem® in women during pregnancy has not been studied. Animal studies have not shown any adverse effects on the developing fetus.

Meronem® it should not be used during pregnancy, except in cases where the potential benefit to the mother from its use exceeds the possible risk to the fetus. In each case, the drug should be used under strict medical supervision.

Lactation

Meropenem is detected in animal breast milk in very low concentrations. Meronem®should not be used during breastfeeding, except in cases where the potential benefit to the mother from using the drug exceeds the possible risk to the child. After evaluating the benefit to the mother, a decision should be made to stop breastfeeding or discontinue taking Meronem®.

Contraindications

• hypersensitivity to meropenem or other carbapenem drugs in the anamnesis;
• severe hypersensitivity (anaphylactic reactions, severe skin reactions) to any antibacterial agent with a beta-lactam structure (i. e., to penicillins or cephalosporins);
• children under 3 months of age.

With caution:  concomitant use with potentially nephrotoxic drugs; patients with gastrointestinal complaints (diarrhea), especially those suffering from colitis.

Side effects

The hematopoietic system:  often-thrombocytosis; infrequently-eosinophilia, thrombocytopenia; rarely-leukopenia, neutropenia, agranulocytosis; very rarely-hemolytic anemia.

The nervous system:  infrequently-headache, paresthesia, fainting, hallucinations, depression, anxiety, increased excitability, insomnia; rarely-convulsions.

GASTROINTESTINAL TRACT:  often — nausea, vomiting, diarrhea, increased activity of hepatic transaminases, alkaline phosphatase, LDH of serum bilirubin concentration; infrequently-constipation, cholestatic hepatitis; very rarely-pseudomembranous colitis.

Skin and subcutaneous tissue:  infrequently-rash, urticaria, pruritus; very rarely-erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

The immune system:  very rarely — angioedema, manifestations of anaphylaxis.

CCC:  infrequently — heart failure, cardiac arrest, tachycardia, bradycardia, myocardial infarction, decrease or increase Blood pressure, thromboembolism of the branches of the pulmonary artery.

Kidneys and urinary tract:  infrequently-an increase in the concentration of creatinine in the blood, an increase in the concentration of urea in the blood.

Respiratory tract:  infrequently-dyspnoea.

Other services:  often-local reactions (inflammation, thrombophlebitis, pain at the injection site); rarely-vaginal candidiasis and candidiasis of the oral mucosa.

How to take, course of use and dosage

The drug Meronem is intended for intravenous use. Dosage 20-40 mg / kg of body weight every 8 hours, maximum dose 1-2 g every 8 hours.

Special instructions

There is no experience of using the drug in pediatric practice in patients with neutropenia or with primary or secondary immunodeficiency.

As with other antibiotics, when using meropenem as monotherapy in patients who are in critical condition with a detected lower respiratory tract infection caused by Pseudomonas aeruginosa or if it is suspected, a regular sensitivity test is recommended.

In rare cases, when using Meronem®, as with almost all antibiotics, pseudomembranous colitis develops, which can vary in severity from mild to life-threatening forms. It is important to keep in mind the possibility of developing pseudomembranous colitis if diarrhea occurs while using Meronem®.

There are clinical and laboratory signs of cross-allergic reactions between other carbapenems and beta-lactam antibiotics, penicillins and cephalosporins. There are rare reports of hypersensitivity reactions (including fatal ones) when using Meronem®, as well as other beta-lactam antibiotics (see the section “Side effects”). Before starting meropenem therapy, the patient should be thoroughly interviewed, paying special attention to the history of hypersensitivity reactions to beta-lactam antibiotics. Meronem® should be used with caution in patients with a history of such events. If there is an allergic reaction to meropenem, then it is necessary to stop the drug use and take appropriate measures.

The use of Meronem® in patients with liver diseases should be carried out under careful monitoring of transaminase activity and bilirubin concentration.

As with the use of other antibiotics, excessive growth of insensitive microorganisms is possible, and therefore constant monitoring of the patient is necessary.

The prevalence of acquired antibiotic resistance of various pathogens may vary depending on the region and time, it is desirable to have up-to-date information about the resistance of common pathogens in a particular region, especially in the treatment of severe infections. If the resistance is such that the effectiveness of the drug against at least some infections becomes questionable, you should consult an expert.

Co-use of Meronem® and valproic acid preparations is not recommended.

The use of the drug for infections caused by methicillin-resistant staphylococcus is not recommended.

Influence on the ability to drive a car and work with equipment. No studies have been conducted on the effect of Meronem® on the ability to drive a car and other equipment. However, it should be taken into account that headache, paresthesia and convulsions may occur when taking Meronem®.

Form of production

Powder for preparation of solution for intravenous use

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

4 years

Active ingredient

Meropenem

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as prescribed by a doctor, for children as prescribed by a doctor

Indications

Respiratory Tract Infections, Infectious Diseases, Urinary Tract Infections, Intestinal Infections, Skin Infections, Pneumonia